Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq. ft. production facilities in Princeton, BC, operating under a Drug Establishment Licence (DEL) and Dealer's Licence (DL).

• Products are available in Australia (for PTSD and TRD) and Canada (via Special Access Program); restricted in the US pending regulatory changes.

• Focused on scaling production, expanding into new markets (US, Israel), and supporting clinical trials through strategic partnerships.

• Winding down nutraceutical business to focus on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349).

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975.

• Accumulated deficit as of December 31, 2025: C$28.3 million.

• Cash and cash equivalents as of December 31, 2025: C$491,750.

• Company has a history of operating losses and recurring negative cash flows from operations.

Use of proceeds and capital allocation

• Net proceeds from the IPO (estimated US$12.2 million) allocated as: 28.7% for scaling production/distribution, 18.0% for market entry to Israel and the US, 53.3% for working capital and operating expenses.

• Management has broad discretion over use of funds; additional capital may be needed for US market entry beyond 12 months.